quinoxalines has been researched along with Triple Negative Breast Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fatima, K; Kaushal, T; Khan, F; Khan, S; Luqman, S; Negi, AS | 1 |
| Hu, MH; Huang, Q; Jin, G; Wu, TY | 1 |
| Bagby, SM; Benaim, E; Capasso, A; Diamond, JR; Eckhardt, SG; Eisen, A; Gittleman, B; Hartman, SJ; Kim, DJ; Lang, J; Lee, YB; Pelanda, R; Pitts, TM; Tentler, JJ; Yacob, BW | 1 |
| Du, J; Huang, X; Lan, W; Lin, W; Long, Z; Ma, W; Wang, L; Yang, Y; Zhang, N; Zheng, B; Zhong, F | 1 |
| Hu, MH; Lin, JH | 1 |
| Battula, VL; Nguyen, K | 1 |
6 other study(ies) available for quinoxalines and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Synthesis, Molecular Docking, and 2D-QSAR Modeling of Quinoxaline Derivatives as Potent Anticancer Agents against Triple-negative Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Molecular Docking Simulation; Quantitative Structure-Activity Relationship; Quinoxalines; Triple Negative Breast Neoplasms; Tubulin | 2022 |
New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; G-Quadruplexes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Quinoxalines; Triple Negative Breast Neoplasms | 2019 |
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Topics: Animals; Apoptosis; beta Catenin; Cell Proliferation; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Quinoxalines; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; China; Cyclohexylamines; Drugs, Chinese Herbal; Female; Ferroptosis; Heme Oxygenase-1; Humans; Iron; Lipid Peroxidation; Medicine, Chinese Traditional; Mice; Mice, Nude; Phenylenediamines; Quinoxalines; Spiro Compounds; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
New Dibenzoquinoxalines Inhibit Triple-Negative Breast Cancer Growth by Dual Targeting of Topoisomerase 1 and the
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; DNA Damage; DNA Topoisomerases, Type I; Down-Regulation; Drug Design; Female; G-Quadruplexes; Humans; Ligands; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-myc; Quinoxalines; Transplantation, Heterologous; Triple Negative Breast Neoplasms | 2021 |
Targeting NFκB signaling in GD2
Topics: Animals; Cell Line, Tumor; Female; Gangliosides; Humans; Imidazoles; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; NF-kappa B; Quinoxalines; Sialyltransferases; Signal Transduction; Triple Negative Breast Neoplasms | 2017 |